In the BioHarmony Drug Report Database

"Preview" Icon

Everolimus

Afinitor, Afinitor Disperz, Zortress, Votubia (everolimus) is a small molecule pharmaceutical. Everolimus was first approved as Afinitor on 2009-03-30. It has been approved in Europe to treat breast neoplasms, pancreatic neoplasms, renal cell carcinoma, and tuberous sclerosis. The pharmaceutical is active against serine/threonine-protein kinase mTOR. In addition, it is known to target Cytochrome P450. Afinitor’s patents are valid until 2028-07-01 (FDA).

 

Trade Name

 

Afinitor, Votubia
 

Common Name

 

everolimus
 

ChEMBL ID

 

CHEMBL1908360
 

Indication

 

breast neoplasms, pancreatic neoplasms, renal cell carcinoma, tuberous sclerosis
 

Drug Class

 

Immunosuppressives: immunosuppressant, rapamycin derivatives

Image (chem structure or protein)

Everolimus structure rendering